Skip to content
Daily Issue
Future
of Work
·
Sign in
Daily Issue → inbox:
Subscribe
F
Feed
E
Explore
B
Build
R
Roles
A
Alerts
Y
You
●
Last issue 3d ago
Goldenrod Therapeutics | Funded Work
← Back to explore
Goldenrod Therapeutics
goldenrodtherapeutics.com
Follow
Biotech
PDE4 inhibitor for clinical development.
Press
Goldenrod Therapeutics raises $6.5 million to test UNMC-created drug that could change modern medicine
Silicon Prairie News · 7/8/2026
Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation
Business Wire · 6/4/2026
Goldenrod Therapeutics: $6.5 Million Seed Round Advances UNMC-Developed Brain Inflammation Therapy Toward Clinical Trials
Pulse 2.0 · 6/10/2026
Fannin-backed Goldenrod Therapeutics raises $6.5M for Friedrich's ataxia treatment
The Business Journals · 6/8/2026
Houston brain health co. secures $6.5M for rare disease study
InnovationMap · 6/12/2026
Funding Timeline
6/9/2026
seed
$6.5M
Ataxia Ventures, Fannin Partners